tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robert Leboyer, 20 are a BUY (90.91%), 2 are a HOLD (9.09%).
Analyst Robert Leboyer, currently employed at NOBLE CAPITAL, carries an average stock price target met ratio of 60.61% that have a potential upside of 54.85% achieved within 350 days.
Robert Leboyer’s has documented 42 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on UNCY, Unicycive Therapeutics at 01-Jul-2026.
Analyst best performing recommendations are on BNTC (BENITEC BIOPHARMA LTD ADR).
The best stock recommendation documented was for BNTC (BENITEC BIOPHARMA LTD ADR) at 4/20/2020. The price target of $238 was fulfilled within 1 day with a profit of $15.98 (7.2%) receiving and performance score of 71.98.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 15-Dec-2022
3 years 7 months 6 days ago
(16-Feb-2023)
2/2 (100%)
$-38.25 (-79.27%)
301
Hold
$6
$5.15 (605.88%)
3 years 9 months 7 days ago
(15-Dec-2022)
1/1 (100%)
$-4.98 (-45.36%)
1
Buy
$7
$-0.86 (-10.94%)
$12
3 years 10 months 20 days ago
(02-Nov-2022)
2/2 (100%)
$-25.13 (-72.62%)
132
Buy Since 03-Jun-2019
4 years 1 months 19 days ago
(03-Aug-2022)
0/3 (0%)
$139.25 (125.73%)
$250
$245.42 (5358.52%)
4 years 5 months 22 days ago
(31-Mar-2022)
0/2 (0%)
$185.75 (289.11%)
Which stock is Robert Leboyer most bullish on?
What Year was the first public recommendation made by Robert Leboyer?
